Position in BLLN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
-$12,183,357 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Derivatives in BLLN
reported options exposure · as of Mar 31, 2026CallValue
$426,276
CallShares
5,400
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $1,657,068,556 across 34 Diagnostics & Research names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
864,489 | $424,922,277 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
1,212,152 | $209,096,220 | |
| 3 | A |
Agilent Technologies, Inc.
|
1,801,714 | $205,359,361 | |
| 4 | DHR |
Danaher Corp /De/
|
1,026,347 | $194,595,390 | |
| 5 | MTD |
Mettler Toledo International Inc/
|
58,054 | $73,217,704 | |
| 6 | GH |
Guardant Health, Inc.
|
775,941 | $71,673,669 | |
| 7 | DGX |
Quest Diagnostics Inc
|
347,218 | $68,047,783 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
390,042 | $66,517,762 |
All Filings in BLLN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $426,276 | 5,400 | Call | Defined | 2026-05-15 | |
| 2025-12-31 | $12,183,357 | 148,868 | Shares | Defined | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||